Drug Combination Details

General Information of the Combination (ID: C10054)
Name Monocyte activating polypeptide II   NP Info  + Temozolomide   Drug Info 
Structure +
Disease
Brain cancer [ICD-11: 2A00]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Expression PIK3CB  Molecule Info 
Pathway MAP
                    In-vitro Model U-87MG ATCC CVCL_0022 Glioblastoma Homo sapiens
U-251MG CVCL_0021 Astrocytoma Homo sapiens
                    In-vivo Model Mice were implanted subcutaneously with GSCs or GSCs stably transfected with pre-miR-590-3p into the right flank regions of mice at 2 * 106 cells density.
                    Experimental
                    Result(s)		 EMAP-II in combination with TMZ suppresse malignant biological behaviors of GSCs via miR-590-3p/MACC1 inhibiting PI3K/AKT/mTOR signaling pathway, and might provide potential therapeutic approaches for human GSCs.
References
Reference 1 Combination of Endothelial-Monocyte-Activating Polypeptide-II with Temozolomide Suppress Malignant Biological Behaviors of Human Glioblastoma Stem Cells via miR-590-3p/MACC1 Inhibiting PI3K/AKT/mTOR Signal Pathway. Front Mol Neurosci. 2017 Mar 13;10:68.
 Download Picture         KEGG Link